Advertisement

Neoadjuvant Therapy for Rectal Cancer

Published:March 09, 2022DOI:https://doi.org/10.1016/j.soc.2021.11.008

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Arnold M.
        • Sierra M.S.
        • Laversanne M.
        • et al.
        Global patterns and trends in colorectal cancer incidence and mortality.
        Gut. 2017; 66: 683-691
        • Salem M.E.
        • Hartley M.
        • Unger K.
        • et al.
        Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its future direction.
        Oncology (Williston Park). 2016; 30: 546-562
        • Monson J.R.T.
        • Weiser M.R.
        • Buie W.D.
        • et al.
        Practice parameters for the management of rectal cancer (revised).
        Dis Colon Rectum. 2013; 56: 535-550
        • Glynne-Jones R.
        • Wyrwicz L.
        • Tiret E.
        • et al.
        Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2017; 28: iv22-iv40
        • Heald R.J.
        • Husband E.M.
        • Ryall R.D.
        The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?.
        Br J Surg. 1982; 69: 613-616
        • Chen T.Y.-T.
        • Wiltink L.M.
        • Nout R.A.
        • et al.
        Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial.
        Clin Colorectal Cancer. 2015; 14: 106-114
        • Sauer R.
        • Becker H.
        • Hohenberger W.
        • et al.
        Preoperative versus postoperative chemoradiotherapy for rectal cancer.
        N Engl J Med. 2004; 351: 1731-1740
        • Sauer R.
        • Liersch T.
        • Merkel S.
        • et al.
        Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
        J Clin Oncol. 2012; 30: 1926-1933
      1. National Comprehensive Cancer Network. NCCN guidelines: rectal cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed December 30, 2021.

        • Heald R.J.
        • Ryall R.D.
        Recurrence and survival after total mesorectal excision for rectal cancer.
        Lancet. 1986; 1: 1479-1482
        • MacFarlane J.K.
        • Ryall R.D.
        • Heald R.J.
        Mesorectal excision for rectal cancer.
        Lancet. 1993; 341: 457-460
        • Pettersson D.
        • Lörinc E.
        • Holm T.
        • et al.
        Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer.
        Br J Surg. 2015; 102 ([discussion 978]): 972-978
        • Swedish Rectal Cancer Trial
        • Cedermark B.
        • Dahlberg M.
        • et al.
        Improved survival with preoperative radiotherapy in resectable rectal cancer.
        N Engl J Med. 1997; 336: 980-987
        • Kapiteijn E.
        • Marijnen C.A.
        • Nagtegaal I.D.
        • et al.
        Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.
        N Engl J Med. 2001; 345: 638-646
        • Sebag-Montefiore D.
        • Stephens R.J.
        • Steele R.
        • et al.
        Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.
        Lancet. 2009; 373: 811-820
        • Peeters K.C.M.J.
        • Marijnen C.A.M.
        • Nagtegaal I.D.
        • et al.
        The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.
        Ann Surg. 2007; 246: 693-701
        • Gérard J.-P.
        • Conroy T.
        • Bonnetain F.
        • et al.
        Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
        J Clin Oncol. 2006; 24: 4620-4625
        • Bosset J.-F.
        • Collette L.
        • Calais G.
        • et al.
        Chemotherapy with preoperative radiotherapy in rectal cancer.
        N Engl J Med. 2006; 355: 1114-1123
        • Roh M.S.
        • Colangelo L.H.
        • O’Connell M.J.
        • et al.
        Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
        J Clin Oncol. 2009; 27: 5124-5130
        • Park J.
        • Yoon S.M.
        • Yu C.S.
        • et al.
        Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
        Cancer. 2011; 117: 3703-3712
        • Rödel C.
        • Martus P.
        • Papadoupolos T.
        • et al.
        Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
        J Clin Oncol. 2005; 23: 8688-8696
        • Park I.J.
        • You Y.N.
        • Agarwal A.
        • et al.
        Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.
        J Clin Oncol. 2012; 30: 1770-1776
        • Fokas E.
        • Liersch T.
        • Fietkau R.
        • et al.
        Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.
        J Clin Oncol. 2014; 32: 1554-1562
        • Ngan S.Y.
        • Burmeister B.
        • Fisher R.J.
        • et al.
        Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.
        J Clin Oncol. 2012; 30: 3827-3833
        • Bosset J.-F.
        • Calais G.
        • Mineur L.
        • et al.
        Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
        Lancet Oncol. 2014; 15: 184-190
        • Maas M.
        • Nelemans P.J.
        • Valentini V.
        • et al.
        Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.
        Lancet Oncol. 2010; 11: 835-844
        • Martin S.T.
        • Heneghan H.M.
        • Winter D.C.
        Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
        Br J Surg. 2012; 99: 918-928
        • Bujko K.
        • Nowacki M.P.
        • Nasierowska-Guttmejer A.
        • et al.
        Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.
        Br J Surg. 2006; 93: 1215-1223
        • Erlandsson J.
        • Holm T.
        • Pettersson D.
        • et al.
        Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.
        Lancet Oncol. 2017; 18: 336-346
        • Erlandsson J.
        • Lörinc E.
        • Ahlberg M.
        • et al.
        Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial,.
        Radiother Oncol, 135,. 2019; : 178-186
        • De Caluwé L.
        • Van Nieuwenhove Y.
        • Ceelen W.P.
        Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer.
        Cochrane Database Syst Rev. 2013; (CD006041)
        • Schmoll H.-J.
        • Haustermans K.
        • Price T.J.
        • et al.
        Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: final results of PETACC-6.
        J Clin Orthod. 2018; 36: 3500
        • Banwell V.C.
        • Phillips H.A.
        • Duff M.J.
        • et al.
        Five-year oncological outcomes after selective neoadjuvant radiotherapy for resectable rectal cancer.
        Acta Oncol. 2019; 58: 1267-1272
        • Rahbari N.N.
        • Elbers H.
        • Askoxylakis V.
        • et al.
        Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials.
        Ann Surg Oncol. 2013; 20: 4169-4182
        • Gérard J.-P.
        • Azria D.
        • Gourgou-Bourgade S.
        • et al.
        Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
        J Clin Oncol. 2010; 28: 1638-1644
        • O’Connell M.J.
        • Colangelo L.H.
        • Beart R.W.
        • et al.
        Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
        J Clin Oncol. 2014; 32: 1927-1934
        • Aschele C.
        • Lonardi S.
        • Cionini L.
        • et al.
        Final results of STAR-01: a randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.
        J Clin Orthod. 2016; 34: 3521
        • Rödel C.
        • Liersch T.
        • Becker H.
        • et al.
        Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
        Lancet Oncol. 2012; 13: 679-687
        • Rödel C.
        • Graeven U.
        • Fietkau R.
        • et al.
        Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2015; 16: 979-989
        • Gollins S.
        • West N.
        • Sebag-Montefiore D.
        • et al.
        A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.
        Br J Cancer. 2018; 119: 697-706
        • Bujko K.
        • Wyrwicz L.
        • Rutkowski A.
        • et al.
        Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study.
        Ann Oncol. 2016; 27: 834-842
        • Ciseł B.
        • Pietrzak L.
        • Michalski W.
        • et al.
        Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
        Ann Oncol. 2019; 30: 1298-1303
        • Schrag D.
        • Weiser M.R.
        • Goodman K.A.
        • et al.
        Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
        J Clin Oncol. 2014; 32: 513-518
        • Schrag D.
        • Weiser M.
        • Saltz L.
        • et al.
        Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance)..
        Clin Trials. 2019; 16: 165-175
        • Cercek A.
        • Roxburgh C.S.D.
        • Strombom P.
        • et al.
        Adoption of total neoadjuvant therapy for locally advanced rectal cancer.
        JAMA Oncol. 2018; 4: e180071
        • Garcia-Aguilar J.
        • Chow O.S.
        • Smith D.D.
        • et al.
        Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
        Lancet Oncol. 2015; 16: 957-966
        • Marco M.R.
        • Zhou L.
        • Patil S.
        • et al.
        Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial.
        Dis Colon Rectum. 2018; 61: 1146-1155
        • Fernandez-Martos C.
        • Garcia-Albeniz X.
        • Pericay C.
        • et al.
        Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial.
        Ann Oncol. 2015; 26: 1722-1728
        • Fokas E.
        • Allgäuer M.
        • Polat B.
        • et al.
        Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12.
        J Clin Oncol. 2019; 37: 3212-3222
      2. Garcia-Aguilar J, Patil S, Jin Kim, et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. Journal of Clinical Oncology 2020 38:15_suppl, 4008-4008.

        • Conroy T.
        • Bosset J.-F.
        • Etienne P.-L.
        • et al.
        Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
        Lancet Oncol. 2021; 22: 702-715
        • Bahadoer R.R.
        • Dijkstra E.A.
        • van Etten B.
        • et al.
        Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2021; 22: 29-42
      3. A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): The final reports. J Clin Oncol.

        • Le D.T.
        • Uram J.N.
        • Wang H.
        • et al.
        PD-1 blockade in tumors with mismatch-repair deficiency.
        N Engl J Med. 2015; 372: 2509-2520
        • André T.
        • Shiu K.-K.
        • Kim T.W.
        • et al.
        Pembrolizumab in microsatellite-instability-high advanced colorectal cancer.
        N Engl J Med. 2020; 383: 2207-2218
        • Rahma O.E.
        • Yothers G.
        • Hong T.S.
        • et al.
        Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial.
        JAMA Oncol. 2021; 7: 1225-1230
        • Longo W.E.
        • Virgo K.S.
        • Johnson F.E.
        • et al.
        Risk factors for morbidity and mortality after colectomy for colon cancer.
        Dis Colon Rectum. 2000; 43: 83-91
        • Bregendahl S.
        • Emmertsen K.J.
        • Lous J.
        • et al.
        Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study.
        Colorectal Dis. 2013; 15: 1130-1139
        • Quezada-Diaz F.
        • Jimenez-Rodriguez R.M.
        • Pappou E.P.
        • et al.
        Effect of neoadjuvant systemic chemotherapy with or without chemoradiation on bowel function in rectal cancer patients treated with total mesorectal excision.
        J Gastrointest Surg. 2019; 23: 800-807
        • Hupkens B.J.P.
        • Martens M.H.
        • Stoot J.H.
        • et al.
        Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection - a matched-controlled study.
        Dis Colon Rectum. 2017; 60: 1032-1040
        • Quezada-Diaz F.F.
        • Smith J.J.
        • Jimenez-Rodriguez R.M.
        • et al.
        Patient-reported bowel function in patients with rectal cancer managed by a watch-and-wait strategy after neoadjuvant therapy: a case-control study.
        Dis Colon Rectum. 2020; 63: 897-902
        • Wang K.
        • Tepper J.E.
        Radiation therapy-associated toxicity: etiology, management, and prevention.
        CA Cancer J Clin. 2021; 71: 437-454